ARTICLES BY LOUIS

• It Could Be At Takeda Or P&G: The Three Pieces of Outsourcing

  3/21/2017

  Three pieces for working with contractors and external supply-chains are Communication, Transparency for Problem Resolution, and Benefit Sharing, says William A. (Al) Kentrup, VP Global Quality Compliance and Systems, Takeda Pharmaceutical Company, and former director of corporate quality at Procter and Gamble.

• The Three Pillars Of Industry Conferences

  3/13/2017

  Every organization – and each individual within – has specific needs and objectives for attending industry conferences. Yet, we can identify three overarching criteria: Go where you can meet customers; Go where you can learn; Go where you can participate. Here’s a look at the possibility of putting all three into practice.

• M&A Crucible in Contract Drug Development And Manufacturing

  3/6/2017

  According to a new industry report, the major contract development and manufacturing organizations only command a 2-4% market share each. Nonetheless, there is substantial M&A activity in the sector, and it certainly feels like we’re on a cusp of major consolidation. Let’s look at the evidence and momentum.

• Adversity On The Path to Global Drug Distribution

  3/3/2017

  Not all Outsourced Pharma readers will have had experiences as pronounced as Jennifer Dent’s. But her narrative can spur us to take a look at our own personal – and organizational – missions within the greater biotech and pharma realm, and point to another area where outsourcing drug development and manufacturing professionals can step up our global leadership.

• High Potency Service Providers: The Contenders And Pretenders

  2/28/2017

  Is your CMO as accomplished at handling high-potency (HP) compounds as you think? Perhaps you’d better learn to separate "the contenders from the pretenders.” Here’s how.

• The “Isle Of Difference” In Contract Development And Manufacturing

  2/24/2017

  On the way to Life Science Leader magazine’s annual CMO Leadership Awards in Manhattan, we detoured to the “Isle of Difference.” This is a location where service providers devise sales and marketing strategies to entice circling customers to put down anchors with them, instead of at a competitor’s shores. 

• Three Experiences Power A Non-Profit's Business Approach

  1/31/2017

  Jennifer Dent is all business. At a nonprofit organization. She thinks that's exactly how it’s supposed to be. She also shares the enthusiasm of a humanitarian on a mission. Reviewing three experiences in the career of Dent, president of BIO Ventures for Global Health (BVGH), one might think none of this should be the case.

• Vaccine Development Skating On Start-Ups

  1/26/2017

  Ernst Soethout formed Virtuvax last year to take advantage of and further propel vaccine development trends, the most important being: “Big Pharma is ‘outsourcing’ R&D.” That in turn is driving the formation of virtual vaccine companies.”

• What Are New Board Members Saying About Outsourcing?

  1/18/2017

  Leaders from Achaogen, Allergan, Genzyme, Pfizer and Shire have joined the Outsourced Pharma Advisory Board. Already, they've provided some bold analysis — and a few grams of guidance — on outsourcing drug development and manufacturing.

• Chemical Development From Cotton Candy To Pharmaceuticals

  1/12/2017

  Sriram Naganathan, Senior Director, Chemical Development, Dermira, wants to be know as the person who: Came, Learned, and Taught. “I believe," he says, “I ended up working at the two best places for me in the world to learn process chemistry, Pfizer and Roche.” Now he teaches Outsourced Pharma readers what you should know for drug development outsourcing.